Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $266 | $270 | $341 | $464 |
| - Cash | $143 | $160 | $180 | $213 |
| + Debt | $13 | $13 | $14 | $14 |
| Enterprise Value | $135 | $123 | $175 | $265 |
| Revenue | $0 | $0 | $1 | -$1 |
| % Growth | 51.7% | -72.9% | 244.9% | – |
| Gross Profit | -$12 | $0 | $1 | -$1 |
| % Margin | -2,731.2% | 100% | 100% | 100% |
| EBITDA | -$35 | $16 | -$21 | -$9 |
| % Margin | -7,808.8% | 5,528.5% | -1,884.8% | 1,249% |
| Net Income | -$36 | $16 | -$18 | -$10 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | 1,350.9% |
| EPS Diluted | -1.38 | 0.6 | -0.68 | -0.069 |
| % Growth | -330% | 188.2% | -885.5% | – |
| Operating Cash Flow | -$16 | -$18 | -$23 | -$7 |
| Capital Expenditures | -$1 | -$3 | -$1 | -$1 |
| Free Cash Flow | -$17 | -$20 | -$24 | -$8 |